National Health Act 1953 - Amendment special arrangements under subsection 100(1) - Chemotherapy Pharmaceuticals Access Program (No. PB 76 of 2010)

Overview

The National Health Act 1953, enacted by the Parliament of Australia, aims to provide timely, reliable, and affordable access to necessary and cost-effective medicines for the Australian community. The Act, specifically under Part VII, regulates the Australian Pharmaceutical Benefits Scheme (PBS), which supplies listed drugs and medicinal preparations as pharmaceutical benefits. In response to the recommendations of the Pharmaceutical Benefits Advisory Committee (PBAC), the Chemotherapy Pharmaceuticals Access Program Arrangements under subparagraph 100(b)(i) were introduced to ensure adequate supply of special pharmaceutical products, particularly chemotherapy pharmaceuticals, to individuals who are receiving medical treatment in circumstances where pharmaceutical benefits cannot be conveniently or efficiently supplied in accordance with Part VII of the Act. This legislative instrument, F2010L02076, made under the authority of subsection 100(1) of the Act, provides for amendments to the Chemotherapy Pharmaceuticals Access Program, reflecting the recommendations of the PBAC and ensuring that chemotherapy pharmaceuticals are accessible to non-admitted patients, day-admitted patients, and patients on discharge from public hospitals.

Scope and Application

The National Health Act 1953 Amendment Special Arrangements under Subsection 100(1) Chemotherapy Pharmaceuticals Access Program applies to the provision of chemotherapy pharmaceuticals to non-admitted patients, day-admitted patients, or patients on discharge at public hospitals. This legislation amends the arrangements under subparagraph 100(b)(i) of the National Health Act, which was initially established by legislative instrument number PB 55 of 2009 and came into effect on 1 July 2009. These amendments, which took effect on 1 August 2010, are designed to ensure that an adequate supply of special pharmaceutical products is available to those who cannot conveniently or efficiently access pharmaceutical benefits under Part VII of the Act. The Act applies to the Commonwealth jurisdiction, and its scope is further defined by the Pharmaceutical Benefits Advisory Committee (PBAC) recommendations, which are incorporated through the legislative instrument. The Act does not specify any exclusions, exemptions, or thresholds, but it allows for the variation or revocation of special arrangements made under subsection 100(1).

Key Provisions

The main operative sections of this legislation are Sections 100(1) and 100(2) of the National Health Act 1953 (the Act). Section 100(1) allows the Minister to make special arrangements for providing an adequate supply of special pharmaceutical products to certain groups, such as those receiving medical treatment under circumstances where pharmaceutical benefits cannot be efficiently supplied or are inadequate. Section 100(2) grants the Minister the authority to vary or revoke any special arrangement made under Section 100(1). These provisions are essential in ensuring that necessary chemotherapy pharmaceuticals are available to non-admitted patients, day-admitted patients, and patients on discharge at public hospitals. The obligations imposed by the Act on the parties it governs include ensuring the availability of listed chemotherapy pharmaceuticals for the specified patient groups. This includes adherence to the amendments outlined in Schedule 1, such as the addition of new indications for Aprepitant and the inclusion of specific treatments like capecitabine in the treatment of metastatic colorectal cancer. Furthermore, the Act requires compliance with the price adjustments listed in Schedule 4, reflecting the approved prices and those claimed by manufacturers. In terms of consequences for breach, the Act does not explicitly state specific offences, penalties, or civil/criminal consequences within the provided text. However, non-compliance with the Act’s provisions or the special arrangements could potentially lead to legal actions under the broader legislative framework governing the National Health Act 1953. The potential penalties could range from administrative sanctions to more severe legal consequences, depending on the nature and extent of the breach. It is important for entities governed by this legislation to ensure strict adherence to the outlined provisions to avoid any adverse outcomes.